Isoniazid induces apoptosis of activated CD4+ T cells: Implications for post-therapy tuberculosis reactivation and reinfection

Journal of Biological Chemistry

Volumn 289, Issue 44, 2014, Pages 30190-30195

  Tousif, Sultan ^b   Singh, Dhiraj Kumar ^c   Ahmad, Shaheer ^a   Moodley, Prashini ^b   Bhattacharyya, Maitree ^d   Van Kaer, Luc ^e   Das, Gobardhan ^a,b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^d UNIVERSITY OF CALCUTTA   (India)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; HYDRAZINE; PATIENT MONITORING; PATIENT TREATMENT;

IMMUNE RESPONSE; INFECTIOUS DISEASE; MYCOBACTERIUM TUBERCULOSIS; POST TREATMENT; RE-INFECTION; SHORT COURSE; THERAPEUTIC AGENTS;

T-CELLS;

DEXAMETHASONE; ISONIAZID; CYTOKINE; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION RISK; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POSTPRIMARY TUBERCULOSIS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MICROBIOLOGY; PHYSIOLOGY; SPLEEN;

ANIMALS; ANTITUBERCULAR AGENTS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; HUMANS; IMMUNOSUPPRESSION; ISONIAZID; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; SPLEEN;

EID: 84908584258     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.C114.598946     Document Type: Article

References (33)

1. World Health Organization (2010) WHO global tuberculosis control report: Summary. Cent. Eur. J. Public Health 18, 237
2. Pawlowski, A., Jansson, M., Sköld, M., Rottenberg, M. E., and Källenius, G. (2012). Tuberculosis and HIV co-infection. PLoS Pathog. 8, e1002464
3. Zumla, A., Raviglione, M., Hafner, R., and von Reyn, C. F. (2013) Tuberculosis. N. Engl. J. Med. 368, 745-755
4. Getahun, H., Gunneberg, C., Granich, R., and Nunn, P. (2010) HIV infection-associated tuberculosis: the epidemiology and the response. Clin. Infect. Dis. 50, Suppl. 3, S201-S207
5. Collins, K. R., Quiñones-Mateu, M. E., Toossi, Z., and Arts, E. J. (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev. 4, 165-176
6. Corbett, E. L., and Watt., C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., and Dye, C. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021
7. Espinal, M. A., Laszlo, A., Simonsen, L., Boulahbal, F., and Kim., S. J., Reniero, A., Hoffner, S., Rieder, H. L., Binkin, N., Dye, C., Williams, R., and Raviglione, M. C. (2001) Global trends in resistance to antituberculosis drugs: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 344, 1294-1303
8. Pablos-Méndez, A., Raviglione, M. C., Laszlo, A., Binkin, N., Rieder, H. L., Bustreo, F., Cohn, D. L., Lambregts-van Weezenbeek, C. S., Kim, S. J., Chaulet, P., and Nunn, P. (1998) Global surveillance for antituberculosis-drug resistance, 1994-1997: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 338, 1641-1649
9. World Health Organization (2004) Anti-tuberculosis drug resistance in the world. in The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance Report No. 3, pp. 16-20, World Health Organization, Geneva, Switzerland
10. Pablos-Mendez, A., Gowda, D. K., and Frieden, T. R. (2002) Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. World Health Organ. 80, 489-495
11. Davies, J. (1996) Origins and evolution of antibiotic resistance. Microbiologia 12, 9-16
12. Nathanson, E., Nunn, P., Uplekar, M., Floyd, K., Jaramillo, E., Lönnroth, K., Weil, D., and Raviglione, M. (2010) MDR tuberculosis: critical steps for prevention and control. N. Engl. J. Med. 363, 1050-1058
13. Falzon, D., Jaramillo, E., Wares, F., Zignol, M., Floyd, K., and Raviglione, M. C. (2013) Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect. Dis. 13, 690-697
14. Velayati, A. A., and Masjedi., M. R., Farnia, P., Tabarsi, P., Ghanavi, J., and Ziazarifi., A. H., and Hoffner, S. E. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136, 420-425
15. Udwadia, Z. F. (2012) Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology 17, 741-742
16. Udwadia, Z. F., and Amale., R. A., Ajbani, K. K., and Rodrigues, C. (2012) Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579-581
17. Fountain, F. F., Tolley, E., Chrisman, C. R., and Self, T. H. (2005) Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128, 116-123
18. Cox, H. S., Morrow, M., and Deutschmann, P. W. (2008) Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336, 484-487
19. den Boon, S., van Lill, S. W., Borgdorff, M. W., Enarson, D. A., Verver, S., Bateman, E. D., Irusen, E., Lombard, C.J., White, N. W., de Villiers, C., and Beyers, N. (2007) High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. Emerg. Infect. Dis. 13, 1189-1194
20. van Rie, A., Warren, R., Richardson, M., Victor, T. C., Gie, R. P., Enarson, D. A., Beyers, N., and van Helden, P. D. (1999) Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 341, 1174-1179
21. + T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur. J. Immunol. 23, 2189-2195
22. Flynn, J. L., Chan, J., Triebold, K. J., Dalton, D. K., Stewart, T. A., and Bloom, B. R. (1993) An essential role for interferon γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249-2254
23. Haanen, J. B., de Waal Malefijt, R., Res, P. C, Kraakman, E. M., Ottenhoff, T. H., de Vries, R. R., and Spits, H. (1991) Selection of a human T helper type 1-like T cell subset by mycobacteria. J. Exp. Med. 174, 583-592
24. Bhattacharya, D., Dwivedi, V.P., Maiga, M., Maiga, M., Van Kaer, L., Bishai, W. R., and Das, G. (2014) Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis. J. Biol. Chem. 289, 16508-16515
25. Chatterjee, S., and Dwivedi., V. P., Singh, Y., Siddiqui, I., Sharma, P., Van Kaer, L., Chattopadhyay, D., and Das, G. (2011) Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a Toll-like receptor-2-dependent manner. PLoS Pathog. 7, e1002378
26. Sweeney, K. A., and Dao., D. N., Goldberg, M. F., Hsu, T., Venkataswamy, M. M., Henao-Tamayo, M., Ordway, D., and Sellers., R. S., Jain, P., Chen, B., Chen, M., Kim, J., Lukose, R., Chan, J., Orme, I. M., Porcelli, S. A., and Jacobs, W. R., Jr. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17:1261-1268
27. Borst, P. (2012) Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2, 120066
28. Devadas, S., Das, J., Liu, C, Zhang, L., and Roberts., A. I., Pan, Z., Moore, P. A., Das, G., and Shi, Y. (2006) Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity 25, 237-247
29. Dietrich, J., and Doherty, T. M. (2009) Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 117, 440-457
30. Gallegos, A. M., van Heijst, J. W., Samstein, M., Su, X., Pamer, E. G., and Glickman, M. S. (2011) A γ interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog. 7, e1002052
31. Raghuvanshi, S., Sharma, P., Singh, S., Van Kaer, L., and Das, G. (2010) Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc. Natl. Acad. Sci. U.S.A. 107, 21653-21658
32. Saha, B., Das, G., Vohra, H., Ganguly, N. K., and Mishra, G. C (1994) Macrophage-T cell interaction in experimental mycobacterial infection: selective regulation of co-stimulatory molecules on Mycobacterium-infected macrophages and its implication in the suppression of cell-mediated immune response. Eur. J. Immunol. 24, 2618-2624
33. Tousif, S., Singh, Y., Prasad, D. V., Sharma, P., Van Kaer, L., and Das, G. (2011) T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One 6, e19864